[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:rhabdoid-tumor":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":82,"states":87},"Rhabdoid Tumor",12,[7,15,22,29,35,41,47,53,59,65,71,77],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05985161","A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors",[11],"Phase 2","RECRUITING","2026-08-26T02:15:51.395565Z","2026-05-05T02:43:28.556798Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06625190","Alpha\u002FBeta T and B Cell Depletion With Zoledronic Acid for Solid Tumors",[19],"Phase 1\u002FPhase 2","2026-08-26T02:19:04.543908Z","2026-07-05T03:45:20.453806Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT06198296","Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells",[26],"Phase 1","2026-08-26T02:16:39.977107Z","2026-05-05T02:43:29.711287Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":33,"content_modified":34},"NCT07148050","Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells",[26],"2026-08-26T02:17:16.126291Z","2026-05-05T02:43:29.698343Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":39,"content_modified":40},"NCT05135975","A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors",[11],"2026-08-26T02:16:46.147215Z","2026-05-05T02:43:28.530799Z",{"nct_id":42,"title":43,"phases":44,"status":12,"updated_at":45,"content_modified":46},"NCT04897321","B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)",[26],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.511090Z",{"nct_id":48,"title":49,"phases":50,"status":12,"updated_at":51,"content_modified":52},"NCT04715191","Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors",[26],"2026-08-26T02:16:35.654046Z","2026-05-05T02:43:27.425045Z",{"nct_id":54,"title":55,"phases":56,"status":12,"updated_at":57,"content_modified":58},"NCT04469530","Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors",[11],"2026-08-26T02:18:49.989941Z","2026-05-05T02:43:27.107017Z",{"nct_id":60,"title":61,"phases":62,"status":12,"updated_at":63,"content_modified":64},"NCT05468359","Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients",[19],"2026-08-26T02:15:38.131683Z","2026-05-05T02:35:31.864168Z",{"nct_id":66,"title":67,"phases":68,"status":12,"updated_at":69,"content_modified":70},"NCT04901702","Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma",[19],"2026-08-26T02:18:32.765187Z","2026-05-05T02:35:31.688370Z",{"nct_id":72,"title":73,"phases":74,"status":12,"updated_at":75,"content_modified":76},"NCT04199741","PET\u002FCT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56",[19],"2026-08-26T02:18:04.640417Z","2026-07-05T05:32:16.773657Z",{"nct_id":78,"title":79,"phases":80,"status":12,"updated_at":57,"content_modified":81},"NCT07698899","A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)",[26],"2026-07-19T19:36:05.081790Z",[83],{"biomarker":84,"count":85,"slug":86},"Glypican-3",3,"glypican-3",[88,92,96,99,102],{"state":89,"count":90,"slug":91},"Texas",5,"texas",{"state":93,"count":94,"slug":95},"New York",4,"new-york",{"state":97,"count":85,"slug":98},"District of Columbia","district-of-columbia",{"state":100,"count":85,"slug":101},"Georgia","georgia",{"state":103,"count":85,"slug":104},"Tennessee","tennessee"]